new glp 1 drugs in development Another milestone the evolution of GLP-1-based diabetes therapies Discovery of GLP-1–Based Drugs for

GLP-1 receptor agonists enhance insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety through central pathways

52 reactions to dulaglutide and 11 reported reactions lixisenatide, no fatalities were reported

The semaglutide injection guide and tirzepatide injection guide walk through the process step by step

Its molecular structure: Approximately 39 amino acids Synthetic, manufactured via Solid-Phase Peptide Synthesis Fatty acid-conjugated for extended biological half-life Rationally designed for balanced activation across GLP-1, GIP, and glucagon receptors The Phase 2 clinical trial data, published in the New England Journal of Medicine in 2023, reported substantial metabolic effects that exceeded what previous-generation single and dual agonists had produced

The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript